Click it and Unblock the Notifications
Sahajanand Medical Technologies Ltd. IPO
IPO Timeline
-
15 Oct 2026Bidding Starts
-
19 Oct 2026Bidding Ends
-
21 Oct 2026Allotment Finalization
-
23 Oct 2026Listing
About Sahajanand Medical Technologies Ltd.
We are a Class III53 and Class C/D54 medical devices company with a portfolio of technologically advanced medical devices across vascular and structural heart intervention. Our Company was founded by Mr. Dhirajlal Kotadia in 2001. According to the F&S Report, we were the first company in the world to receive a CE certification for a DES with a biodegradable polymer- based paclitaxel-eluting stent (Infinnium). Over the years, we have introduced several innovative products, driven by our focus on research and development and precision manufacturing capabilities enabling us to deliver quality products backed by clinical data, with a presence across 65 countries (including India) in the three months ended June 30, 2026 and 77 countries (including India) in Fiscal 2026.
We are a R&D-driven company engaged in the development of Class III and Class C/D medical devices, with an emphasis on Vascular Intervention (“VI”) and Structural Heart (“SH”). Our portfolio of (i) VI products includes coronary intervention products such as coronary stents and coronary balloons, (ii) SH products include TAVI and Occluders, and (iii) Others including our own brand of renal stents, peripheral DCBs and other trading products.
Sahajanand Medical Technologies Ltd. IPO Reservation
| Investors Category | Shares Offered |
|---|---|
| Anchor Investors | 40,71,635 (29.46%) |
| Employee Reserved | 2,50,000 (1.81%) |
| Non Institutional Investors | 20,35,817 (14.73%) |
| Qualified Institutional Buyers (QIBs) | 27,14,423 (19.64%) |
| Retail Individual Investors (RIIs) | 47,50,241 (34.37%) |
Sahajanand Medical Technologies Ltd. Financial Information
| Year End | Revenue | PAT | Reserves & Surplus |
|---|---|---|---|
| 31 Mar 2026 | 557.25 Cr | 43.50 Cr | 667.53 Cr |
| 31 Mar 2025 | 537.82 Cr | 7.11 Cr | 611.85 Cr |
Sahajanand Medical Technologies Ltd. Background
-
2016Samara Capital Markets Holding Limited invested around ₹400 million by subscribing to 9,406,419 Equity Shares of our Company. Additionally, Samara Capital Markets Holding Limited also purchased 9,406,419 Equity Shares of our Company from existing shareholders for a consideration around ₹400 million
-
2017Samara Capital Markets Holding Limited invested ₹700 million by subscribing to 13,717,421 Equity Shares of our Company
Enrolment of 1,435 patients completed for TALENT trial on the safety and efficacy of a sirolimus eluting coronary stent
-
2018NHPEA Sparkle Holding B.V. invested ₹1,600 million by subscribing to 16,396,803 Equity Shares of our Company
-
2019TALENT trial study for Supraflex presented by Professor Patrick Serruys and published in The Lancet
Received EC Certificate for full quality assurance system granted to Supraflex Cruz
Acquired Imex Salud S.L. to establish direct operations in Spain, for a sum of € 2.55 million
Acquired 75% of the quotas of SMT Brazil (erstwhile Zarek Distribuidora De Produtos Hospitalares Eireli) to establish hybrid operations in Brazil, for a sum of R$ 18.82 million
-
2020Acquired VCL (as an erstwhile subsidiary of our Company) for a consideration of ₹687.29 million
Acquired Vascular Innovations, a wholly owned subsidiary of SMT Ireland, for a sum of ₹443.00 million
-
2022Publication of the safety and performance study of “Hydra TAVI” in JACC: Cardiovascular Interventions, demonstrating its efficacy in the treatment of symptomatic severe aortic stenosis
-
2024Launch of Hydra TAVI in Russia, Malaysia and Hungary
Completion of patient enrolment for TUXEDO-2, a clinical trial to evaluate the efficacy of drug eluting stent “Supraflex Cruz” in diabetic patients with multi vessel coronary artery disease
TGA Australia’s approval for drug eluting stent “Supraflex Cruz”
Publication of S-FLEX UK-II Registry study on “Supraflex Cruz” demonstrating its clinical safety and performance in BMJ Open
Publication of the Compare 60/80 HBR trial study in Circulation: Cardiovascular Interventions demonstrating the efficacy of “Supraflex Cruz” in high bleeding risk patients
-
2025SMT Ireland, our wholly owned Subsidiary, purchased shares of the common stock of SNP Medical Corporation
Publication of 3 year follow up outcomes of the FIRE Trial of “Supraflex Cruz” in Jama Cardiology, demonstrating sustained clinical benefits of Supraflex Cruz in older patients (>75 years) with myocardial infarction and multivessel disease
Publication of 30 day and 6 months follow up outcomes of the GENESIS -II study of Hydra Transcatheter heart valve device in Asia Intervention and Euro PCR 2025, respectively, demonstrating its safety and performance in treating severe aortic stenosis in high risk patients
Presentation of the results of TUXEDO-2, multivessel TALENT trial and Cruz Senior Study, along with results of SFlex Netherlands Registry demonstrating the non inferiority, proven safety, efficacy, and consistent performance of the Supraflex Cruz across a broad spectrum of complex patient populations, at Transcatheter Cardiovascular Therapeutics 2025
1. carry out the Offer for Sale of 13,822,116 Equity Shares of face value of ? 1 each aggregating up to ? [?] million by the Selling Shareholders which constitutes 13.60% of the pre-Offer Equity Share capital of the Company
2. Achieve the benefits of listing the Equity Shares on the Stock Exchanges
1. Bhargav Dhirajlal Kotadia
2. Dhirajlal Vallabhbhai Kotadia
3. Priyanka Dhirajlal Cohen
4. Shree Hari Trust
Major segments of the Indian Medical device industry include Equipment and Electronics, Disposables and Consumables, IVD equipment and Reagents, Implants, Surgical Instruments and other devices. India is counted among the top 20 global medical device markets in terms of value. The Indian Medical ... Read more
FAQs
When does Sahajanand Medical Technologies Ltd. IPO opens and closes?
Sahajanand Medical Technologies Ltd. IPO opens from 15th October to 19th October 2026.What is the size of Sahajanand Medical Technologies Ltd. IPO?
The size of the Sahajanand Medical Technologies Ltd. IPO is ₹475.48 Cr.What is the price range of Sahajanand Medical Technologies Ltd. IPO?
The price range of Sahajanand Medical Technologies Ltd. IPO is at ₹327 to ₹344 per share.What is the minimum investment and lot size required for the Sahajanand Medical Technologies Ltd. IPO?
The minimum investment required is ₹14,792 and minimum lot size is 43 shares.When is Sahajanand Medical Technologies Ltd. IPO listing date?
The Sahajanand Medical Technologies Ltd. IPO will be listed on 23rd October 2026.What is the objective of Sahajanand Medical Technologies Ltd. IPO?
1. carry out the Offer for Sale of 13,822,116 Equity Shares of face value of ? 1 each aggregating up to ? [?] million by the Selling Shareholders which constitutes 13.60% of the pre-Offer Equity Share capital of the Company2. Achieve the benefits of listing the Equity Shares on the Stock Exchanges
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article
Sign in with Google